ESTRO 2022 - Abstract Book

S908

Abstract book

ESTRO 2022

Poster (digital): Head and neck

PO-1073 NLR and PLR ratio as predictive markers of outcomes in head and neck squamous cell carcinoma

L. Gasparini 1 , M. Borgia 1 , M. Trignani 1 , A. Di Pilla 1 , A. Porreca 2 , M. Di Nicola 3 , D. Genovesi 1,4

1 SS. Annunziata Hospital, Radiation Oncology Unit, Chieti, Italy; 2 D'Annunzio University of Chieti-Pescara, Department of Economics, Pescara, Italy; 3 Laboratory of Biostatistics, Department of Medical, Oral and Biotechnological Sciences, Chieti, Italy; 4 G. D'Annunzio University, Department of Neuroscience, Imaging and Clinical Sciences, Chieti, Italy Purpose or Objective The identification of biomarkers for oncologic outcomes could guide risk-adapted treatment strategies. High neutrophil-to- lymphocyte ratio (NLR) is a marker of systemic inflammation and together with the platelet-to-lymphocyte ratio (PLR) is associated with worse outcomes in several solid tumours. The aim of this study was to investigate the prognostic value of NLR and PLR in patients with head and neck squamous cell carcinoma (HNSCC) treated with primary or adjuvant (chemo)radiotherapy ((C)RT) and to correlate this parameters to acute toxicity. Materials and Methods A retrospective analysis of 67 consecutive patients with HNSCC was performed. Blood samples were obtained within 15 days before treatment start. Endpoints of interest were overall survival (OS), local recurrence (LR), distant metastasis (DM), and acute toxicity defined according to CTCAE v4. Univariate Cox proportional hazards models were used to study influence of NLR and PLR used both in the continuum and stratified above and below the median value. To assess differences in median for NLR and PLR for acute toxicity groups we used the Kruscal Wallis test. After grouping the patients with toxicity grade G0 and G1, we used the Mann U-Whitney test to assess differences for the Ratio variables. All statistical analyses were performed using R statistical software (version 3.1.2.). Results Sixty-seven patients with HNSCC were considered. All patients were candidate for curative RT intent. Primary CRT was administered in 23 patients (34.3%), primary RT alone in 9 patients (13.4%), adjuvant (C)RT in 35 (52.3%). Tumours were